These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 32451342)

  • 41. [Sleep-profile of a 72-year-old depressive female patient. Depression and sleep disorders. Significance--causes--treatment].
    Fortschr Neurol Psychiatr; 1998 May; 66(5 Suppl Depression):1-4. PubMed ID: 9696996
    [No Abstract]   [Full Text] [Related]  

  • 42. [Depression and sleep disorders. Progress in antidepressive therapy with nefazodone].
    Nervenarzt; 1998 Jun; 69(6 Suppl Ein Fortsc):1-4. PubMed ID: 9697100
    [No Abstract]   [Full Text] [Related]  

  • 43. A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity.
    De Boer P; Drevets WC; Rofael H; van der Ark P; Kent JM; Kezic I; Parapatics S; Dorffner G; van Gerven J; Beneš H; Keicher C; Jahn H; Seiden DJ; Luthringer R
    J Psychopharmacol; 2018 Jun; 32(6):668-677. PubMed ID: 29848147
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Quetiapine may complete the best match with suvorexant in psychiatric patients with insomnia.
    Murata T
    Int J Clin Pharmacol Ther; 2021 Apr; 59(4):341-342. PubMed ID: 33355087
    [No Abstract]   [Full Text] [Related]  

  • 45. A new class of sedative/hypnotics: dual orexin receptor antagonists.
    Simonson W
    Geriatr Nurs; 2014; 35(6):462-3. PubMed ID: 25457290
    [No Abstract]   [Full Text] [Related]  

  • 46. A Review of Suvorexant, Doxepin, Ramelteon, and Tasimelteon for the Treatment of Insomnia in Geriatric Patients.
    Edmonds C; Swanoski M
    Consult Pharm; 2017 Mar; 32(3):156-160. PubMed ID: 28270270
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Suvorexant-Induced Delirium.
    Yoshida K; Nakamura K; Yasui-Furukori N
    Prim Care Companion CNS Disord; 2018 Nov; 20(6):. PubMed ID: 30476370
    [No Abstract]   [Full Text] [Related]  

  • 48. Possible Suicidal Risk With Daridorexant, a New Treatment for Insomnia.
    Nobile B; Olié E; Courtet P
    J Clin Psychiatry; 2022 Dec; 84(1):. PubMed ID: 36479953
    [No Abstract]   [Full Text] [Related]  

  • 49. [Sitagliptin. DPP-4 inhibitors as a useful extension of oral diabetes therapy?].
    Matthes J; Faust M
    Dtsch Med Wochenschr; 2008 Oct; 133(43):2233-7. PubMed ID: 18924057
    [No Abstract]   [Full Text] [Related]  

  • 50. Insight Into Reduction of Wakefulness by Suvorexant in Patients With Insomnia: Analysis of Wake Bouts.
    Svetnik V; Snyder ES; Tao P; Scammell TE; Roth T; Lines C; Herring WJ
    Sleep; 2018 Jan; 41(1):. PubMed ID: 29112763
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Suvorexant in Patients with Insomnia: Pooled Analyses of Three-Month Data from Phase-3 Randomized Controlled Clinical Trials.
    Herring WJ; Connor KM; Snyder E; Snavely DB; Zhang Y; Hutzelmann J; Matzura-Wolfe D; Benca RM; Krystal AD; Walsh JK; Lines C; Roth T; Michelson D
    J Clin Sleep Med; 2016 Sep; 12(9):1215-25. PubMed ID: 27397664
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial.
    Michelson D; Snyder E; Paradis E; Chengan-Liu M; Snavely DB; Hutzelmann J; Walsh JK; Krystal AD; Benca RM; Cohn M; Lines C; Roth T; Herring WJ
    Lancet Neurol; 2014 May; 13(5):461-71. PubMed ID: 24680372
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Use of Suvorexant for Sleep Regulation in an Adolescent with Early-Onset Bipolar Disorder.
    Prieto DI; Zehgeer AA; Connor DF
    J Child Adolesc Psychopharmacol; 2019 Jun; 29(5):395. PubMed ID: 31033344
    [No Abstract]   [Full Text] [Related]  

  • 54. Nefazodone in primary insomnia: an open pilot study.
    Wiegand MH; Galanakis P; Schreiner R
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Nov; 28(7):1071-8. PubMed ID: 15610919
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The discovery and structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia.
    Lavrador-Erb K; Ravula SB; Yu J; Zamani-Kord S; Moree WJ; Petroski RE; Wen J; Malany S; Hoare SR; Madan A; Crowe PD; Beaton G
    Bioorg Med Chem Lett; 2010 May; 20(9):2916-9. PubMed ID: 20347297
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant.
    Herring WJ; Snyder E; Budd K; Hutzelmann J; Snavely D; Liu K; Lines C; Roth T; Michelson D
    Neurology; 2012 Dec; 79(23):2265-74. PubMed ID: 23197752
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of suvorexant on sleep architecture and power spectral profile in patients with insomnia: analysis of pooled phase 3 data.
    Snyder E; Ma J; Svetnik V; Connor KM; Lines C; Michelson D; Herring WJ
    Sleep Med; 2016 Mar; 19():93-100. PubMed ID: 27198953
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A Greater Extent of Insomnia Symptoms and Physician-Recommended Sleep Medication Use Predict Fall Risk in Community-Dwelling Older Adults.
    Chen TY; Lee S; Buxton OM
    Sleep; 2017 Nov; 40(11):. PubMed ID: 29029240
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of suvorexant on sleep apnea in patients with heart failure: A protocol of crossover pilot trial.
    Shitara J; Kasai T; Akihiro S; Yatsu S; Matsumoto H; Suda S; Ogita M; Yanagisawa N; Fujibayashi K; Nojiri S; Nishizaki Y; Ono N; Suwa S; Daida H
    J Cardiol; 2019 Jul; 74(1):90-94. PubMed ID: 30737183
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Therapeutic use and adverse events of incretin-related drugs].
    Ishikawa M; Yamada Y
    Nihon Rinsho; 2012 May; 70 Suppl 3():699-702. PubMed ID: 22768601
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.